section name header

Pronunciation ⬇

doe-FET-il-ide audio

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

Therapeutic Effects:

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed (>90%) following oral administration.

Distribution: Unknown.

Metabolism/Excretion: 80% excreted by kidneys via cationic renal secretion, mostly as unchanged drug; 20% excreted as inactive metabolites; some metabolism in the liver via cytochrome P450 system (CYP3A4 isoenzyme).

Half-life: 10 hr.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: VENTRICULAR ARRHYTHMIAS (INCLUDING TORSADES DE POINTES), chest pain, QT interval prolongation.

Neuro: dizziness, headache.

Interactions ⬆ ⬇

Drug-Drug:

Drug-Food:

Route/Dosage ⬆ ⬇

Dosing should be adjusted according to renal function and assessment of QT interval

Renal Impairment

Implementation ⬆ ⬇

US Brand Names ⬆ ⬇

Tikosyn

Classifications ⬆ ⬇

Therapeutic Classification: antiarrhythmics (class III)

Availability ⬆ ⬇

(Generic available)

Time/Action Profile ⬆ ⬇

(blood levels)

ROUTEONSETPEAKDURATION
POwithin hrs2–3 hr†12–24 hr

†Steady state levels are achieved after 2–3 days.

Assessment ⬆ ⬇

Lab Test Considerations:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

Code ⬆

NDC Code*